Daprodustat

Drug Profile

Daprodustat

Alternative Names: 1278863; GSK-1278863; GSK-1278863A

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antianaemics; Pyrimidines; Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Prolyl hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia
  • Phase II Perioperative ischaemia
  • Phase I Diabetic foot ulcer; Tendon injuries
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 28 Nov 2016 GlaxoSmithKline initiates enrolment in a phase III trial for Anaemia (in haemodialysis patients with renal anaemia) in Japan (PO) (NCT02829320)
  • 28 Nov 2016 GSK initiates enrolment in a phase III trial for Anaemia (Treatment-experienced) in Japan (PO) (NCT02969655)
  • 21 Nov 2016 GlaxoSmithKline plans a phase III trial for Anaemia (Treatment-experienced) in Japan (PO, Tablet) (NCT02969655)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top